Societal costs of ovarian cancer in a population-based cohort – a cost of illness analysis
It is often forgotten that the impact of ovarian cancer is greater than the immediate consequences of the disease. This population-based study looked at the direct and indirect costs to society resulting from ovarian cancer, for 283 women with ovarian cancer.
Direct costs are the price of medical care. Indirect costs are the result of loss of earnings and opportunity for the patient and their carer.
Results from the survey showed that during the 6 year period after diagnosis the total cost per patient was about €200,000 or €30,000 each year. The cost per year decreased with longer survival. These patients pre-dated the development of precision therapy with PARPi. It is encouraging to realise that although the direct costs have increased with PARPi, because of longer survival, it may well be that the society cost is about the same or possibly decreased.
No comments:
Post a Comment